TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO Share Price
Certificat
DE000SW3EG89
| Market Closed - Boerse Frankfurt Warrants 20:42:55 21/05/2024 BST | ||
| 3.59 EUR | -5.28% |
|
| Current month | -8.46% | ||
| 1 month | -18.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 3.57 | -5.80% |
| 20/05/24 | 3.79 | -2.32% |
| 17/05/24 | 3.88 | 0.00% |
| 16/05/24 | 3.88 | +2.65% |
| 15/05/24 | 3.78 | -5.26% |
Real-time Boerse Frankfurt Warrants
Last update May 21, 2024 at 08:42 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3EG8 |
| ISIN | DE000SW3EG89 |
| Date issued | 13/09/2023 |
| Strike | 1,192 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 5.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.43 € |
|---|---|
| Lowest since issue | 3.57 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- Certificat
